z-logo
Premium
In vitro antiproliferative effect of six Salvia species on human tumor cell lines
Author(s) -
Fiore Giovina,
Nencini Cristina,
Cavallo Federica,
Capasso Anna,
Bader Ammar,
Giorgi Giorgio,
Micheli Lucia
Publication year - 2006
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.1911
Subject(s) - salvia , traditional medicine , biology , cell culture , in vitro , pharmacognosy , mtt assay , botany , pharmacology , biological activity , biochemistry , medicine , genetics
This study was designed to examine the in vitro antiproliferative activity of the methanol crude extracts of six Salvia species: Salvia dominica L. leaves, Salvia lanigera Desf. aerial parts, Salvia menthaefolia Ten. roots, Salvia palaestina Benth. aerial parts, Salvia sclarea L. roots and Salvia spinosa L. aerial parts. Extracts were screened for their possible antitumoral activity by MTT test on nine human cancer cell lines: glioblastoma (DBTRG‐05MG, T98G, U‐87MG), colorectal adenocarcinoma (WiDr and HT‐29), prostate adenocarcinoma (MDA Pca2b), choriocarcinoma (JEG‐3), endometrium adenocarcinoma (HEC‐1A) and B lymphoblast (CIR). IC 50 values were determined for only five extracts and ranged from 90 to 400 mg/mL approximately. Salvia menthaefolia extract exhibited marked antiproliferative activity against all tumor cell lines showing lower IC50 values, while S. spinosa , S. sclarea and S. dominica extracts showed a degree cytotoxic activity dependent on the cell line type. Finally S. palaestina extract revealed a moderate antiproliferative effect only against three cell lines. Salvia lanigera extract displayed toxic activity at all concentrations tested. The results strengthen the evidence that the genus Salvia could be considered a natural resource of potential antitumor agents. Copyright © 2006 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here